Overview of Dolko

Property	Description
Active Ingredient	Acetaminophen (Paracetamol)
Pharmaceutical Forms	Tablets, Oral Solutions, Suppositories
Pharmacological Class	Non-opioid Analgesic; Antipyretic
General Purpose	Symptomatic relief from pain and fever
Origin	Synthetic Chemical Compound

Dolko is a monocomponent pharmaceutical preparation containing the active ingredient Acetaminophen, globally recognized by the International Nonproprietary Name (INN) Paracetamol. This drug entity is classified as a non-opioid analgesic and an antipyretic. The substance is a synthetic chemical compound, specifically a para-aminophenol derivative, and is recognized as a fundamental component in healthcare systems worldwide.

Definition and Pharmacological Classification

The core identity of Dolko is established by its single active substance, Acetaminophen, which acts predominantly within the central nervous system. Acetaminophen is effective for pain and fever relief, serving as a fundamental over-the-counter medicine. Dolko's formulation allows it to act centrally to relieve symptoms without inducing the significant peripheral anti-inflammatory effects associated with other analgesic classes.

Composition, Origin, and Available Pharmaceutical Forms

The formulation of Dolko originates entirely from a synthetic chemical compound, which guarantees a controlled and consistent purity of the Acetaminophen component. As a monocomponent formulation, it delivers a focused therapeutic effect. Dolko is designed for both oral and rectal administration, depending on the presentation. Common pharmaceutical preparations include traditional oral tablets, liquid oral solutions—often designed to be palatable for specific patient groups—and suppositories, ensuring flexibility in patient care.

General Purpose and Mechanism Principle

The general purpose of the Dolko preparation is to provide effective symptomatic relief by modulating the body's response to pain and elevated temperature. This function is achieved by influencing the central nervous system to elevate the pain threshold, resulting in an antinociceptive effect. Furthermore, the drug supports the body’s heat regulation mechanisms, which directly results in its antipyretic capability. Its established use includes addressing discomfort, such as general body aches or high temperature during a typical mild illness.

Regulatory References

What side effects are possible with Dolko?

Possible side effects and safety information

The safety profile for Dolko, which contains Acetaminophen (Paracetamol), is defined by officially documented adverse reactions categorized by frequency and system involvement, with a focus on two rare but serious systemic risks: hepatic injury and severe skin reactions.

Adverse Reaction Scope

Element	Official Regulatory Description
Key Adverse Reaction Categories	Hepatotoxicity, Severe Cutaneous Adverse Reactions (SCARs), Hypersensitivity Reactions, Hematologic Dyscrasias.
Frequency Classification	Common reactions include Nausea, Vomiting, Headache, and Insomnia. Rare reactions include Urticaria and Anaphylaxis. Very Rare reactions include hematologic issues such as Thrombocytopenia and Leucopenia, and the most serious cutaneous reactions.
System-Organ Classes Involved	Hepato-biliary Disorders, Skin and Subcutaneous Tissue Disorders, Gastrointestinal Disorders, Nervous System Disorders, Blood and Lymphatic System Disorders, and Immune System Disorders.
Serious Adverse Reactions	Acute Liver Failure has been associated with use, especially at doses exceeding the maximum recommended daily amount, and can result in the need for a liver transplant or death. Severe Skin Reactions (SJS, TEN, AGEP) are also very rare but are officially documented as potentially fatal outcomes.
Population-Specific Safety Considerations	The drug is formally contraindicated in patients with severe hepatic impairment or severe active liver disease. Caution is also advised for use in individuals with severe renal impairment.
Dose- or Exposure-Related Patterns	The risk of severe hepatic injury is explicitly linked to exceeding the maximum recommended daily dose from all sources.

Resulting Safety Structure

The safety profile is primarily structured to highlight the critical restriction against exceeding the maximum recommended daily dose, which is the major risk factor for acute liver failure. This is complemented by the classification of potential adverse reactions by frequency and the required caution in patient groups with severe hepatic or renal impairment. The profile defines the potential occurrence of less severe effects, such as gastrointestinal and nervous system disturbances, alongside the very rare possibility of severe immunological and hematologic complications.

Overdose and Emergency Response

The official regulatory profile for Dolko overdose emphasizes the potential for severe, dose-dependent hepatotoxicity, which can lead to acute liver failure, necessitate liver transplantation, and result in death. Early symptoms of overdose, such as nausea, vomiting, abdominal pain, and pallor, are often non-specific and do not reliably reflect the severity of the underlying liver damage, which may not fully manifest for several days.

Immediate medical attention is critically required following any suspected ingestion exceeding the recommended limit. Regulatory authorities mandate that individuals seek medical help right away and contact a Poison Control Center (or equivalent service), even if no signs or symptoms are present. Risk of severe liver injury is heightened for individuals with underlying liver disease, alcoholism, or chronic malnutrition.

Due to the time-sensitive nature of the overdose, clinical management involves obtaining a serum acetaminophen concentration at least four hours post-ingestion to guide treatment. The specific antidote used to prevent or lessen hepatic injury is N-acetylcysteine (NAC), and laboratory monitoring of hepatic enzymes (ALT/AST) and INR is required to assess progression.

Therapeutic Uses of Dolko

What Dolko Treats: Main Uses and Benefits

Dolko, which contains the active ingredient acetaminophen (paracetamol), is applied across domains where additional symptomatic support is needed. It is relevant in clinical settings marked by heightened patient distress, and provides supportive relief when symptoms are more noticeable.

The medication is commonly used for managing mild to moderate pain and to reduce fever, demonstrating its two core therapeutic functions.

Relief of Pain and Systemic Discomfort

The medication is relevant for easing symptoms related to physical discomfort across a wide spectrum of mild to moderate pain manifestations. Dolko is commonly used to help with: headache, muscle aches (myalgia), dental pain, sore throat, and discomfort associated with primary dysmenorrhea or osteoarthritis. This supportive function is applied in addressing symptom clusters that may become intense or disruptive, especially when they interfere with routine activities.

Fever Management and Acute Scenarios

Dolko is primarily used in situations involving a feverish state (pyrexia), which is often associated with acute symptomatic episodes like the common cold or influenza. It is commonly used across conditions characterized by periods of heightened symptoms or those involving episodic manifestations, such as post-vaccination discomfort. This antipyretic function is relevant for managing symptoms that create noticeable physiological strain and contributes to easing the overall symptom burden for both the general adult and pediatric populations.

Quick Fact: Relief for Fever and Mild Pain

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Dolko, which contains acetaminophen (paracetamol), has strict population eligibility criteria defined by government regulatory bodies. Use of the medicine is contraindicated and must not occur in patients with a documented history of hypersensitivity to acetaminophen or any of its inactive ingredients. Furthermore, the medicine is absolutely prohibited for individuals diagnosed with severe hepatic impairment or severe active liver disease.

Usage is restricted and requires caution in several other patient groups. This includes individuals with severe renal impairment (creatinine clearance le 30 mL/min) and patients with pre-existing mild-to-moderate hepatic impairment. Official labeling also advises patients with chronic alcoholism (specifically those consuming three or more alcoholic drinks per day) against using the medicine.

Eligibility by age is formulation-dependent; standard adult-strength preparations are not recommended for children under 10 years of age. For pregnant and breastfeeding women, use is generally considered compatible, but caution is advised to use the lowest effective dose for the shortest period, as documented in regulatory guidelines.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Dolko (Acetaminophen/Paracetamol) is defined by officially documented effects on drug exposure and pharmacodynamic risks, as detailed in government regulatory labeling.

Documented Interactions Affecting Drug Exposure

Interactions that alter the concentration of Acetaminophen are officially recorded:

Interacting Substance	Official Description of Effect
Probenecid	Reduces clearance of Acetaminophen by inhibiting conjugation, which necessitates dose considerations.
Isoniazid	Decreases Acetaminophen clearance, potentially increasing its systemic action.
Metoclopramide / Domperidone	Accelerate the absorption of Acetaminophen.
Cholestyramine	Reduces absorption of Acetaminophen.

Pharmacodynamic and Metabolic Risks

Oral Anticoagulants (e.g., Warfarin): The anticoagulant effect may be enhanced by prolonged regular daily use of Acetaminophen, officially increasing the risk of bleeding. This effect is not noted with occasional use.
CYP2E1 Enzyme Inducers: Substances like Phenytoin, Carbamazepine, and Rifampicin can alter Acetaminophen metabolism, increasing its hepatotoxic potential and sometimes decreasing its drug level (AUC).
Zidovudine and Flucloxacillin: Co-administration with Zidovudine is associated with increased neutropenia. Concurrent use with Flucloxacillin is officially linked to the risk of High Anion Gap Metabolic Acidosis.

Substance and Population Constraints

The regulatory label includes specific constraints for administration:

Timing Rule: Acetaminophen must be taken at least 1 hour before or 4 hours after Cholestyramine to ensure sufficient absorption.
Alcohol: Consumption of three or more alcoholic drinks per day is officially warned to significantly increase the risk of severe liver damage (hepatotoxicity).
Other Products: Regulatory advice strictly warns against taking any other product containing Acetaminophen concurrently.
Population Note: Caution is noted for populations with conditions such as Chronic Alcoholism or Severe Renal Impairment due to altered risk or clearance of the substance.

Mechanism of Action

Dolko, containing acetaminophen (paracetamol), exerts its mechanism through central nervous system modulation and enzymatic inhibition. The molecule acts as a non-selective inhibitor of cyclooxygenase enzymes (COX-1, COX-2) within the central nervous system, which may be due to its interaction with the peroxidase active site of the enzyme. This central inhibition restricts the biosynthesis of prostaglandins, particularly prostaglandin E2, in the hypothalamus and spinal cord.

Beyond COX inhibition, the compound may engage the endocannabinoid system by acting as a precursor for the formation of a compound that serves as an agonist at the transient receptor potential vanilloid 1 ( TRPV1) receptor. Activation of TRPV1 leads to an increased neuronal activity and downstream signaling, which contributes to the compound's overall effects. Additionally, the compound is noted to influence serotonergic descending inhibitory pathways. The combined central reduction in prostaglandin-mediated signaling and modulatory interaction with the TRPV1 and serotonergic systems results in a net system-level physiological modulation of thermoregulation and afferent neuronal signal transmission.

Dosage and Administration Information

How to Use Dolko: Official Administration Guidelines

Official instructions for using Dolko (Acetaminophen/Paracetamol) define specific parameters regarding dosage, frequency, and route of administration. Adherence to these guidelines, especially the maximum limits and required intervals, is critical.

Administration Scope and Dosage

Feature	Official Guideline
Approved Routes	Oral (PO), Rectal (PR), and Intravenous (IV) injection are authorized.
Standard Dosing	Adult single doses are typically 650 mg or 1,000 mg.
Maximum Total Dose	The cumulative total intake from all sources (oral, rectal, IV) must not exceed 4,000 mg in a 24-hour period.
Dosing Frequency	Immediate-release forms require a minimum interval of 4 hours between doses; administration is typically scheduled for every 4 or 6 hours. Extended-release formulations are scheduled every 8 hours.

Special Populations and Procedural Constraints

Official labeling mandates specific adjustments for certain populations. For adults weighing under 50 kg, dosing must be weight-based. Patients with severe renal impairment require extension of the dosing interval, while those with hepatic impairment are often limited to a reduced total daily dosage (e.g., 2,000 mg/day) for short-term use.

The medication may be taken with or without food. For the intravenous route, the solution must be administered via a 15-minute infusion and must not be given as a rapid injection. All liquid and pediatric oral forms must be measured using the dedicated calibrated dosing device supplied with the product to ensure dose accuracy.

These instructions define the standardized, label-based approach for the proper administration of the medicine.

Recent Clinical Evidence

Dolko: Recent Clinical Evidence

The clinical foundation for Dolko, which contains the active ingredient acetaminophen, is based on a large volume of official regulatory and peer-reviewed scientific literature. This evidence includes numerous Randomized Controlled Trials (RCTs), Systematic Reviews, and Meta-analyses conducted in various patient groups and settings, contributing to the comprehensive body of evidence.

Evidence for use in Acute Pain Relief

Research has extensively explored the use of acetaminophen in a variety of acute situations characterized by episodic or disruptive symptoms of physical discomfort. Studies focus on conditions such as headache, dental pain, and pain experienced after surgical procedures.

Studies describing patterns suggesting that the medicine was studied for short-term relief, with measured changes in pain scores typically observed within the first few hours after administration. Comparative studies reported that measured outcomes were similar to various active treatments. Different routes of administration (such as oral versus intravenous forms) were observed to result in minor variations in the speed of onset of the measured effects.

Evidence for use in Fever Management

Acetaminophen was evaluated in a large research base for conditions characterized by temporary physiological imbalance (fever).

The core evidence comes from RCTs designed to study acute symptom changes, particularly in the pediatric population (infants and children). Studies monitored key physiological outcomes related to systemic imbalance, primarily the change in core body temperature over defined time intervals and the duration of the temperature-lowering effect.

Research highlights changes measured during the study period, consistently showing a decrease in measured body temperature across diverse febrile populations following administration. Studies explored whether it measured a greater temperature change compared to placebo in reducing fever.

Research Gaps and Unanswered Questions

Despite the extensive research base, the evidence highlights what is known and what is still uncertain:

Chronic Conditions: Findings were mixed regarding the benefit of continuous use for certain chronic pain conditions, particularly chronic low back pain, where evidence quality varies across studies.
Long-Term Effects: There is limited information for long-term outcomes regarding the repeated, continuous use of acetaminophen, especially for periods exceeding several months.
Special Populations: Regarding pregnancy, regulatory reviews have concluded that while some observational studies have suggested a statistical association with neurodevelopmental outcomes, the results were inconclusive and a causal link has not been established.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dolko (FAQ)

Q: How does Dolko compare to other pain relief medicines in general terms?

A: Official documents classify the active ingredient in Dolko as a non-opioid analgesic and an antipyretic. This designation puts it into a different pharmacological class than nonsteroidal anti-inflammatory drugs (NSAIDs) or opioid pain relievers. Comparisons between classes of medicine are often complex and are not typically made in official regulatory documentation.

Q: How long does it usually take for Dolko to start working?

A: According to the official clinical pharmacology information, the onset of action for the medicine when taken orally is generally noted to occur within the first 30 to 60 minutes. Onset can vary depending on the specific formulation and the route of administration used.

Q: Is it normal to feel slightly tired when first starting Dolko?

A: The official product information lists common side effects that include nausea, vomiting, headache, and insomnia (difficulty sleeping). Any minor feelings or persistent effects should be discussed with a healthcare professional.

Q: Is it safe to take Dolko with my blood pressure medicine?

A: Official drug information advises reviewing all concurrent medications, including blood pressure medicine, with a healthcare professional. This review is necessary to help assess the potential risk of any drug-drug interactions, which can affect the effectiveness or safety of either medicine.

Q: Is Dolko safe for older adults (seniors) to use?

A: Official labeling notes the need for caution and potential dosage adjustments in certain individuals, including those with pre-existing conditions like severe hepatic or renal impairment. Any use should be in accordance with the official administration instructions provided on the drug label.

Q: What are some common misunderstandings people have about how Dolko works?

A: The drug's mechanism is described as working predominantly in the central nervous system to relieve pain and fever. This is distinct from some other analgesics that act primarily by reducing inflammation throughout the body. Therefore, its primary function is not anti-inflammatory.

Q: Why do some people say Dolko makes them feel 'foggy'?

A: The officially documented safety profile includes adverse reactions classified under Nervous System Disorders. Although the term 'foggy' is not explicitly listed, common side effects that may affect alertness include headache and insomnia (difficulty sleeping). The overall impact on mental status can vary among individuals.

Q: What is the maximum amount of time someone can take Dolko?

A: The administration of Dolko is typically for short-term symptomatic relief of acute conditions. Official evidence notes that there is limited information regarding long-term outcomes for continuous, repeated use exceeding several months. The recommended duration is typically kept to the shortest effective period.

Q: Why is my doctor asking me about my medical history before prescribing Dolko?

A: Official regulatory documents specify that the medicine is contraindicated or requires caution in patients with a history of certain conditions. Examples include severe liver or kidney impairment, necessitating a full review of a patient's medical history prior to use.

Q: Is it true that Dolko should not be used by people with a specific non-life-threatening pre-existing condition (e.g., certain eye conditions)?

A: Official regulatory restrictions on using the drug are primarily limited to conditions such as severe hepatic impairment, severe active liver disease, severe renal impairment, and known hypersensitivity to the drug. Other non-life-threatening conditions are not typically listed as contraindications in official labeling.

Q: What clinical trials led to the approval of Dolko?

A: Regulatory approval is based on a large body of scientific literature, including numerous clinical trials. These studies, such as Randomized Controlled Trials (RCTs), are reviewed by governing bodies to confirm the drug’s intended use for pain and fever relief.

Q: What does it mean that Dolko has a known drug-drug interaction with another drug?

A: A drug-drug interaction is described in official documents as when one substance changes the intended effect or the systemic exposure (concentration) of the other substance in the body. This is why official warnings list substances that affect the concentration or action of Dolko.

Q: What is the usual duration of treatment with Dolko?

A: Official information indicates that the drug is studied and intended for the short-term symptomatic relief of acute pain and fever. This short-term use pattern is reflected in the official administration guidelines, which define dosing frequency and daily limits.

Q: Can Dolko affect my mood or cause changes in behavior?

A: The officially documented safety profile includes adverse reactions classified under Nervous System Disorders. Although specific mood changes are not always explicitly listed, side effects such as headache and insomnia are included in the documented warnings.

Q: Is Dolko considered a 'strong' or 'mild' medicine?

A: The official classification for the active ingredient is as a non-opioid analgesic and an antipyretic. Regulatory documents use these objective terms to describe its pharmacological category, rather than subjective terms like 'strong' or 'mild.'

Q: What is the risk of becoming dependent on Dolko?

A: Official classification designates the active ingredient as a non-opioid analgesic. It is not subject to scheduling under the U.S. Controlled Substances Act, indicating a lack of regulatory designation for abuse potential.

Q: How long does Dolko stay in your system after you stop taking it?

A: Based on the official clinical pharmacology data, the elimination half-life of the active ingredient is typically between 1.9 to 2.5 hours in healthy adults. This half-life describes how quickly the medicine is removed from the body.

Q: What is the difference between a 'black box warning' and a standard warning for Dolko?

A: The U.S. FDA has required the most serious warning, known as a Boxed Warning (Black Box Warning), on prescription products containing the active ingredient. This warning is used to highlight the potential for severe outcomes, such as severe liver injury.

Q: What does it mean if Dolko is described as a Schedule X drug?

A: Official regulatory information states that the active ingredient is classified as a non-opioid analgesic. It is not subject to scheduling under the Controlled Substances Act (CSA) in the U.S., which means it is not regulated as a controlled substance.

Q: Can Dolko affect my ability to drive or operate machinery?

A: The official safety profile lists side effects such as insomnia and headache, which are classified under Nervous System Disorders. Users should be aware that caution may be necessary when performing tasks that require full alertness if they experience these effects.

Q: What should I do if my side effects from Dolko get worse?

A: Regulatory documents state that users should stop using the medicine and seek immediate medical help if signs of a serious reaction occur. These signs include swelling, difficulty breathing, or symptoms indicative of liver injury.

Q: How do regulatory bodies classify the safety profile of Dolko?

A: Regulatory bodies worldwide recognize the active ingredient as an essential medicine and classify it as a non-opioid analgesic and antipyretic. The safety profile is defined by officially documented contraindications, warnings, and adverse reactions classified by frequency.

Q: Does Dolko interact with contraceptive pills?

A: Official interaction data indicates that hormonal contraceptives may decrease or delay the effect of the active ingredient. However, concurrent use at usual therapeutic doses is generally not associated with significant additional risk that would warrant a contraindication.

Q: Is Dolko a type of sedative?

A: The active ingredient in Dolko is officially classified as a non-opioid analgesic and antipyretic. It is not classified as a sedative.

How should Dolko be stored and disposed of?

Dolko, an acetaminophen product, must be stored under specific conditions to maintain its effectiveness and ensure household safety, according to regulatory labeling.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at controlled room temperature (20 C to 25 C) and away from excessive heat (above 40 C).
Environment	Keep the medicine in a dry place, protected from light, and do not freeze it.
Packaging	Store in the original container, which must be kept tightly closed and away from moisture.

All forms of Dolko must be kept out of the sight and reach of children, as accidental ingestion can be harmful. This is a mandatory safety instruction found on the official label.

Disposal Instructions

Unused or expired Dolko must be disposed of in line with local requirements. The preferred method is using a drug take-back location or a mail-back program. If these are unavailable, the medicine should be removed from its original packaging, mixed with an undesirable substance (e.g., dirt), sealed in a container, and placed in the household trash. Do not flush this medicine down the toilet.

Dolko